{"id":"W2139204856","doi":"10.1056/nejmoa0902533","title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1007,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"UCB Pharma; EMD Serono; Genentech; Multiple Sclerosis Society of Canada; Sanofi; Bayer HealthCare; Vertex Pharmaceuticals; Teva Pharmaceutical Industries; Acorda Therapeutics; Ironwood Pharmaceuticals, Incorporated; Biogen; Pfizer","keywords":"Cladribine; Medicine; Multiple sclerosis; Placebo; Relapsing remitting; Oral administration; Clinical trial; Internal medicine; Oncology; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001567783,0.001156518,0.002805971,0.000361689,0.0004363362,0.0007355595,0.0007601593,0.00178603,0.006893505],"category_scores_gemma":[0.001858573,0.0004719343,0.001195141,0.0002967423,0.001109349,0.0006828464,0.0003582426,0.002415593,0.0008944733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005413116,"about_ca_system_score_gemma":0.0007906684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005406477,"about_ca_topic_score_gemma":0.0008339174,"domain_scores_codex":[0.9993413,0.0003751031,0.0000493607,0.0001068975,0.00004688792,0.00008041027],"domain_scores_gemma":[0.9988255,0.0003489895,0.0002655436,0.00009420107,0.00006918199,0.0003966373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9854997,0.002730899,0.0001877831,0.0003375244,0.0002548929,0.00002381709,0.00001549964,0.0001152665,0.00158951,0.00002982163,0.0002573624,0.008957881],"study_design_scores_gemma":[0.9517289,0.04606523,0.00123568,0.00002459731,0.000118875,0.0000236118,0.000007708263,0.0001759516,0.0002292539,0.00004703605,0.0003369628,0.00000612509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843318,0.00687283,0.0006038579,0.0008826568,0.0008452521,0.00358024,0.000977479,0.000149717,0.001756222],"genre_scores_gemma":[0.9891375,0.002297006,0.001066177,0.0009172183,0.0004708687,0.003457092,0.000761657,0.00001457195,0.001878025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006893505,"threshold_uncertainty_score":0.0230611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08532440594402674,"score_gpt":0.3402950320820509,"score_spread":0.2549706261380242,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}